Purple Biotech (PPBT) Accounts Payables (2015 - 2026)

Purple Biotech (PPBT) has 12 years of Accounts Payables data on file, last reported at $843000.0 in Q1 2026.

• Accounts Payables for Q1 2026 came in at $843000.0, down 2.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $843000.0 (down 2.88% YoY), and the FY2025 annual result was $2.1 million, up 42.27% from the prior year.
• Accounts Payables declined to $843000.0 in Q1 2026 per PPBT's latest filing, from $2.1 million in the prior quarter.
• Over five years, Accounts Payables peaked at $3.5 million in Q4 2023 and troughed at $605000.0 in Q3 2025.
• A 5-year average of $1.9 million and a median of $1.9 million in 2024 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2024 and 2025: Accounts Payables soared 93.51% in 2024, then sank 78.01% in 2025.
• A 5-year view of Accounts Payables shows it stood at $2.1 million in 2022, then soared by 65.67% to $3.5 million in 2023, then tumbled by 58.81% to $1.5 million in 2024, then surged by 42.27% to $2.1 million in 2025, then sank by 59.28% to $843000.0 in 2026.
• Business Quant data shows PPBT's Accounts Payables at $843000.0 in Q1 2026, $2.1 million in Q4 2025, and $605000.0 in Q3 2025.